Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2016-02-29 Interim / Quarterly Rep…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Half Yearly Report and Accounts 20 pages 261.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D Half-Year Statement' and covers the period ended 31 December 2015. It includes detailed financial results for the half-year period, such as revenue, net loss, net tangible assets, and cash position. It also contains a Directors' Report, Auditor's Independence Declaration, condensed consolidated interim financial statements (income statement, balance sheet, cash flows, changes in equity), notes to the interim financial statements, directors' declaration, and an independent auditor's review report. The content is comprehensive and includes actual financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2016
2016-02-29 English
Appendix 4C - quarterly 4 pages 29.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, payments to directors, reconciliation of cash, and compliance statements. The report covers a quarter ended 31 December 2015 and includes substantive financial data and analysis for that period. The length of the document (6611 characters) and the detailed financial content indicate it is a full quarterly financial report rather than a brief announcement or certification. The presence of actual financial statements and cash flow details aligns with the definition of an Interim / Quarterly Report (IR). Q2 2015
2016-01-28 English
Director Appointment 1 page 21.0KB
Board/Management Information Classification · 100% confidence The document announces the appointment of a new non-executive director, Ms Stephanie Unwin, to the company's board. It provides background information on her experience and the strategic benefit to the company. There is no financial data, no report attached or referenced, and no mention of voting results or other regulatory filings. This fits the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2016-01-17 English
Initial Director's Interest Notice 2 pages 20.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, with no securities held. This is a report of personal share transactions or interests by a company director. The document length is short and focused solely on director interests, matching the definition of Director's Dealing filings. Therefore, the appropriate classification is DIRS (Director's Dealing).
2016-01-17 English
Combination therapy escalates potency of Phylogica peptides 3 pages 53.9KB
Capital/Financing Update Classification · 90% confidence The document is a press release announcing scientific research results and grant funding related to Phylogica's cancer drug development program. It discusses independent study outcomes, collaboration grants, and company background. There is no mention of financial results, regulatory filings, management changes, voting results, or any formal report submission. The content is promotional and informational about research progress and funding, typical of a Capital/Financing Update or general company announcement. Given the focus on grant funding and research collaboration, the best fitting category is Capital/Financing Update (CAP). The document length is 7369 characters, which is consistent with a detailed announcement rather than a brief notice or full report. Therefore, the classification is CAP with high confidence.
2015-12-08 English
Shareholder Briefings 1 page 19.9KB
Investor Presentation Classification · 95% confidence The document is a short announcement about upcoming shareholder/investor briefings hosted by Phylogica Limited, including dates, locations, and contact information. It does not contain any financial data, detailed presentations, or reports. It is not a transcript of a call, nor a formal report like an annual or interim report. The content is consistent with an Investor Presentation announcement or invitation to attend such a presentation. Given the nature of the document as a briefing invitation and update on company progress and strategy, the most appropriate classification is Investor Presentation (IP). The document length is short and focused on event details rather than full report content, supporting this classification. Confidence is high due to clear context and content type.
2015-11-26 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.